MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.
The combination of mitomycin C, methyl-CCNU and 5-fluorouracil produced no objective tumor regressions in 25 evaluable patients with metastatic colorectal carcinoma. Patients who achieved stable disease survived significantly longer than patients who had progressive disease. This difference appeared to be more probably related to pre-treatment characteristics of the patients than caused by treatment. Serial CEA determinations revealed a parallel relationship with tumor behavior in 17 of 19 patients.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage* / Q000633:toxicity; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008130:Lomustine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000633:toxicity; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage* / Q000633:toxicity; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012075:Remission, Spontaneous; D013997:Time Factors
D008937:Mitomycins; D009607:Nitrosourea Compounds; D008130:Lomustine; D005472:Fluorouracil